This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In this discussion of ‘commercially reasonable efforts,’ Dr. Greg Bell explains how understanding the strategy behind a pharmaceutical product launch can inform development obligations in contract and licensing agreements. Click below to read the article.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comIn recent years, the adoption of advanced treatments in inflammatory bowel disease has evolved. Oral products have captured a significant share in ulcerative...
The study examines the global policy landscape for invasive fungal infections, identifies key policy gaps, and underscores the need for stronger policy...
CRA is a proud sponsor of the event. Kaitlyn Austin presents the session titled “Securing Insight Alignment to Drive Future-Proofed Strategies and...
CRA is a proud sponsor of the largest annual gathering of Medical Affairs professionals, globally. Ayushman Ghosh and Brooke Bonet present the roundtable...
